- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
More ▼
Key statistics
On Wednesday, Mirum Pharmaceuticals Inc (MIRM:NMQ) closed at 25.72, 11.15% above the 52 week low of 23.14 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.02 |
---|---|
High | 26.40 |
Low | 24.82 |
Bid | 24.66 |
Offer | 27.04 |
Previous close | 25.11 |
Average volume | 440.73k |
---|---|
Shares outstanding | 47.12m |
Free float | 45.18m |
P/E (TTM) | -- |
Market cap | 1.18bn USD |
EPS (TTM) | -4.08 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:15 BST.
More ▼